Yield10 Bioscience (OTCPK:YTEN) - Aandelenkoers, Nieuws & Analyse

YTEN Overzicht aandelen

Yield10 Bioscience, Inc. is een agrarisch biowetenschapsbedrijf dat zich richt op de commercialisering van producten op basis van Camelina-oliezaden in de Verenigde Staten. Meer informatie

YTEN fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	2/6
Dividenden	0/6

Risicoanalyse

Negatief eigen vermogen

Heeft geen betekenisvolle marktkapitalisatie ( $364K )

Heeft een omzet van minder dan 1 miljoen USD ( $750K )

De winst is de afgelopen 5 jaar met 5.5% per jaar gedaald

+ 2 meer risico's

Yield10 Bioscience, Inc. Concurrenten

Endonovo Therapeutics

OTCPK:ENDV

US$317.5k

Bellerophon Therapeutics

OTCPK:BLPH

US$672.8k

Capstone Holding

OTCPK:CAPS

US$504.4k

NovelStem International

OTCPK:NSTM

US$520.4k

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Yield10 Bioscience
Historische aandelenkoersen
Huidige aandelenkoers	US$0.50
52 Week Hoogtepunt	US$17.26
52 Week Laag	US$0.35
Bèta	1.43
11 maand verandering	-28.57%
3 maanden verandering	-65.04%
1 Jaar Verandering	-91.51%
33 jaar verandering	-99.59%
5 jaar verandering	-99.58%
Verandering sinds IPO	-100.00%

Recent nieuws en updates

Recent updates

Yield10 Bioscience GAAP EPS of $0.70 beats by $1.39, revenue of $0.1M misses by $0.06M

Aug 10

Is Yield10 Bioscience (NASDAQ:YTEN) In A Good Position To Invest In Growth?

Nov 12

Yield10 Bioscience (NASDAQ:YTEN) Is In A Good Position To Deliver On Growth Plans

Jul 19

Yield10 Bioscience, Inc.'s (NASDAQ:YTEN) CEO Will Probably Find It Hard To See A Huge Raise This Year

May 18

Here's Why We're Watching Yield10 Bioscience's (NASDAQ:YTEN) Cash Burn Situation

Apr 14

Rendement voor aandeelhouders

	YTEN	US Biotechs	US Markt
7D	19.1%	2.4%	2.2%
1Y	-91.5%	16.2%	31.7%

Rendement versus industrie: YTEN presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 16.2 % opleverde.

Rendement versus markt: YTEN presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 31.7 % opleverde.

Prijsvolatiliteit

Is YTEN's price volatile compared to industry and market?
YTEN volatility
YTEN Average Weekly Movement	37.1%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van YTEN is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van YTEN is het afgelopen jaar gestegen van 31% naar 37%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1992	29	Olly Peoples	www.yield10bio.com

Yield10 Bioscience, Inc. is een agrarisch biowetenschappelijk bedrijf dat zich richt op de commercialisering van producten die gebruik maken van Camelina-oliezaden in de Verenigde Staten. De producten omvatten Camelina-olie voor de productie van hoge niveaus van de omega-3 vetzuren eicosapentaanzuur (EPA) en docosahexaanzuur (DHA); en voor gebruik als een koolstofarme grondstofolie voor biobrandstoffen, waaronder biodiesel, hernieuwbare diesel (RD) en duurzame vliegtuigbrandstof (SAF). Het bedrijf was voorheen bekend als Metabolix, Inc. en veranderde zijn naam in Yield10 Bioscience, Inc. in januari 2017.

Yield10 Bioscience, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Yield10 Bioscience zich tot de beurswaarde?
YTEN fundamentele statistieken
Marktkapitalisatie	US$363.66k
Inkomsten(TTM)	-US$12.70m
Inkomsten(TTM)	US$750.00k

0.5x

P/S-verhouding

0.0x

Koers/Winstverhouding

Is YTEN overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
YTEN resultatenrekening (TTM)
Inkomsten	US$750.00k
Kosten van inkomsten	US$7.21m
Brutowinst	-US$6.46m
Overige uitgaven	US$6.25m
Inkomsten	-US$12.70m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-18.34
Brutomarge	-860.93%
Nettowinstmarge	-1,693.60%
Schuld/Eigen Vermogen Verhouding	-16.0%

Hoe presteerde YTEN op de lange termijn?

Bekijk historische prestaties en vergelijking

YTEN Overzicht aandelen

Risicoanalyse

Yield10 Bioscience, Inc. Concurrenten

OTCPK:ENDV

US$317.5k

OTCPK:BLPH

US$672.8k

OTCPK:CAPS

US$504.4k

OTCPK:NSTM

US$520.4k

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Yield10 Bioscience, Inc. announced that it has received $3 million in funding

Nuseed Nutritional US Inc. entered into an asset purchase agreement to acquire Substantially all assets of Yield10 Bioscience, Inc./Yield10 Oilseeds, Inc. from Yield10 Bioscience, Inc. (OTCPK:YTEN) and Yield10 Oilseeds, Inc. for $5 million.

Yield10 Bioscience, Inc.(OTCPK:YTEN) dropped from NASDAQ Composite Index

Yield10 Bioscience Announces Delisting from Nasdaq

Yield10 Bioscience Announces 1-for-24 Reverse Stock Split to Increase the Market Price Per Share of the its Common Stock to Maintain the Listing of its Common Stock on The Nasdaq Capital Market

Yield10 Bioscience, Inc., Annual General Meeting, Jun 07, 2024

Recent updates

Yield10 Bioscience, Inc. announced that it has received $3 million in funding

Nuseed Nutritional US Inc. entered into an asset purchase agreement to acquire Substantially all assets of Yield10 Bioscience, Inc./Yield10 Oilseeds, Inc. from Yield10 Bioscience, Inc. (OTCPK:YTEN) and Yield10 Oilseeds, Inc. for $5 million.

Yield10 Bioscience, Inc.(OTCPK:YTEN) dropped from NASDAQ Composite Index

Yield10 Bioscience Announces Delisting from Nasdaq

Yield10 Bioscience Announces 1-for-24 Reverse Stock Split to Increase the Market Price Per Share of the its Common Stock to Maintain the Listing of its Common Stock on The Nasdaq Capital Market

Yield10 Bioscience, Inc., Annual General Meeting, Jun 07, 2024

Yield10 Bioscience Receives Written Notice from The Nasdaq Stock Market LLC Regarding Not Eligible for Second 180 Day Compliance Period for the Minimum Bid Price Rule Deficiency

Yield10 Bioscience, Inc. to Report Q4, 2023 Results on Apr 01, 2024

Yield10 Bioscience, Inc. Announces the Plant Biosafety Office of the Canadian Food Inspection Agency Clear Genome-edited E3902 Camelina for Planting in Canada

Nasdaq Hearings Panel Grants Yield10 Bioscience, Inc. an Additional Extension to Remain Listed on the Nasdaq Capital Market Until May 13, 2024

Yield10 Bioscience, Inc. Provides an Update on Its Omega-3 Camelina Program

Yield10 Bioscience, Inc. Files Request for Regulatory Status Review with USDA-APHIS for Camelina Designed to Produce the EPA and DHA Components of Omega-3 Oil

Yield10 Bioscience Receives Non-Compliance Notice From Nasdaq

Yield10 Bioscience, Inc. Contemplates Bankruptcy.

Yield10 Bioscience, Inc. Contemplates Bankruptcy.

Yield10 Bioscience, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Yield10 Bioscience, Inc. Provides Update on Recent Advancements in the Development of Elite Herbicide Tolerant Camelina

Yield10 Bioscience, Inc. Receives Non-Compliance Notice from Nasdaq

Yield10 Bioscience, Inc. has completed a Composite Units Offering in the amount of $3.7375 million.

Price target decreased by 33% to US$9.83

Second quarter 2023 earnings released: US$0.64 loss per share (vs US$0.70 loss in 2Q 2022)

New major risk - Shareholder dilution

Yield10 Bioscience, Inc. to Report Q2, 2023 Results on Aug 14, 2023

New major risk - Market cap size

Yield10 Bioscience, Inc. Announces Positive Results in the First Field Test of Stacked Herbicide Tolerance Traits in Camelina

New minor risk - Share price stability

Yield10 Bioscience Files Request for Regulatory Status Review Under Usda-Aphis’S Secure Rule Covering Elite Camelina Designed to Produce the EPA Component of Omega-3 Oil

Yield10 Bioscience Receives A Deficiency Letter from Nasdaq Regarding Minimum Stockholders' Equity Requirement for Continued Listing on the Nasdaq Capital Market

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Insider recently bought US$1m worth of stock

Yield10 Bioscience, Inc. to Report Q1, 2023 Results on May 10, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to US$14.67

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to US$14.67

Yield10 Bioscience, Inc. Begins Winter 2022/2023 Field Test and Seed Production Program

Yield10 Bioscience, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Yield10 Bioscience, Inc. Appoints Willie Loh to Its Board of Directors

Yield10 Bioscience, Inc. Appoints Willie Loh to Its Board of Directors

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Yield10 Bioscience GAAP EPS of $0.70 beats by $1.39, revenue of $0.1M misses by $0.06M

Yield10 Bioscience, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Yield10 Bioscience, Inc. to Report Q1, 2022 Results on May 11, 2022

Price target decreased to US$15.33

Yield10 Bioscience, Inc., Annual General Meeting, May 25, 2022

Yield10 Bioscience, Inc., Annual General Meeting, May 25, 2022

Price target decreased to US$17.00

Yield10 Bioscience Announces Recent Advances in the Development of Camelina as A Production Platform for PHA Bioplastic

Yield10 Bioscience, Inc. Announces an Update on the Camelina Line E3902 Development Program

Yield10 Bioscience, Inc. to Report Q4, 2021 Results on Mar 09, 2022

Is Yield10 Bioscience (NASDAQ:YTEN) In A Good Position To Invest In Growth?

Third quarter 2021 earnings released: US$0.49 loss per share (vs US$0.87 loss in 3Q 2020)

Consensus revenue estimates fall to US$890.0k

Price target decreased to US$21.50

Second quarter 2021 earnings released: US$0.64 loss per share (vs US$0.92 loss in 2Q 2020)

Yield10 Bioscience (NASDAQ:YTEN) Is In A Good Position To Deliver On Growth Plans

Yield10 Bioscience, Inc. Begins 2021 Field Test and Seed Scale Up Program